Researchers at the University of California, Davis have discovered a new class of ROR-γ inhibitors which can reduce and reverse cancer cell resistance to anticancer drugs.
The use of concurrent cancer therapies (chemotherapy, radiation therapy, hormone deprivation therapy, etc.) is typical in cancer treatment due to the development of drug-resistance and mutations in cancer cells. As a result, there is a constant need for new drugs and treatments to treat cancer. There is a need, as future therapies are developed, to maintain cancer cell sensitivity to the anticancer drugs.
Researchers at the University of California, Davis have discovered ROR-γ inhibitors which can reduce and even reverse cancer cell resistance to anticancer drugs. These phenyl-sulfonamide derivatives can be administered in combination with existing anticancer drugs. The derivatives are effective against a wide range of cancers, allowing for different delivery compositions and delivery mechanisms into the body, making it suitable for pharmaceutical use in both animals and people. The inhibitors have been synthesized and verified in vitro in lung, breast, liver, ovarian, endometrial, colon, lymph, glial and other cancer cell types. They have also been verified in vivo in a xenograft mouse model with human cancer cells.
|Patent Cooperation Treaty||Reference for National Filings||2017127442||07/27/2017||2016-496|
ROR-gamma inhibitor, reverse cancer cell resistance, reduce cancer cell resistance, re-sensitize